top of page



Eric Heil, MBA
Managing Partner, Medical Excellence Capital

Eric Heil, MBA, is a venture capital investor turned entrepreneur turned venture capitalist again with extensive experience across the healthcare industry. He currently serves as the managing partner at Medical Excellence Capital, LLC, a $150M early stage life science venture fund founded by patients for patients. He holds board positions at Nobias Therapeutics and GC Therapeutics and is the co-founder and board chair of ProJenX, a company focused on therapies for brain diseases like ALS.
He also serves as a board advisor to the Medical Excellence Foundation, a 501c3 non-profit organization, and is an active member of the Faith-Driven Investor movement.  Prior to his current role, Eric cofounded and led two venture-backed companies, including Upward Health and RightCare. Eric began his career in venture capital as an investment professional at Domain Associates, LLC, the oldest biotech focused venture fund in the country. Eric’s academic background includes a bachelor’s in systems engineering from the University of Pennsylvania and an MBA from Wharton. He currently resides in Bucks County, PA with his family of 5 children. 
Frederick (Rick) Jones headshot.JPG

Frederick "Rick" Jones, MD, MBA
Partner BioAdvance

Rick Jones, MD, MBA, is with BioAdvance. Dr. Jones has over 30 years in the life science industries, serving in roles as physician, executive, consultant, director and investor. At BioAdvance he is responsible for investments in therapeutics and medical devices and serves on the Board of Envara and RightAir. 
Previously Dr. Jones was a director at Broadview Ventures, a Boston-based philanthropic venture fund focused on breakthrough technologies in cardiovascular disease. At Broadview Ventures, Dr. Jones has served as director on the board of Aeromics and Nido Surgical, and as observer on the boards of Aria CV, Ischemia Care and Remedy Pharmaceuticals. Prior to Broadview Dr. Jones served as CEO of Anchor Therapeutics, a venture-backed company, which was developing a platform based on peptide modulators of GPCRs.  Prior to Anchor, Dr. Jones held executive positions with Devgen NV and BioRexis. Dr. Jones began his industry career at Wyeth Pharmaceuticals, initially in Global Medical Affairs and subsequently in Global Business Development.

Dr. Jones is a board-certified internal medicine physician who practiced in the U.S. Navy, the Lahey Clinic and at the University of Pennsylvania. His three degrees are from the University of Pennsylvania.

Kathie Jordan, PhD
Managing Director at Ben Franklin Technology Partners 

Kathie Jordan is the managing director of the Healthcare Investment Group at Ben Franklin Technology Partners, Southeast, where she leads an investment portfolio of 70+ early stage companies. She was previously at Drexel University, where she led the Coulter-Drexel Translational Research Partnership, an endowed non-dilutive fund of health care technologies, ranging from small molecule therapeutics to medical devices and diagnostics. Technologies that were initially supported by the program have been licensed to over a dozen startups, with multiple products now on the market. 
Prior to joining Drexel, she was the director of the Coulter program at the University of Washington, where she also worked in the technology transfer office. She has served as a speaker, panelist and moderator on the topic of university technology commercialization in the life science space, and was an adviser to the C3i program, which trains early-stage biomedical project teams in the commercialization of their innovations, and has been a reviewer for NSF, NIH, and the Flinn Foundation. Kathie spent her early career studying drosophila ovarian development and the role of the innate immune pathways in mouse and endothelial models of sepsis. She has a PhD in molecular and cellular biology from the University of Washington and a BS in biology with honors from Haverford College.

James E. Nelson, MBA
Partner, Venable LLP

Jim Nelson is a co-chair of the Technology, Media and Commercial Group, a member of the firm’s Management Committee, and partner-in-charge of Venable's San Francisco office. Jim focuses on intellectual property-centered businesses that emphasize the development, production and commercialization of IP assets. He manages a range of commercial contract and outsourcing engagements, in addition to general corporate work forming and financing companies and supporting them in mergers, sales, acquisitions and joint ventures. His clients range from emerging growth to Fortune 50 companies—often located or acting globally—in technology, media and entertainment, music, life sciences, financial services and hospitality, among others.
In his IP transactions work, Jim focuses on the revenue side of his client’s business, supporting clients creating value through the use of IP. This includes providing strategic business advice and drafting and negotiating commercial agreements. He has broad experience in the life sciences field working with agreements covering all aspects of innovation and product development as well as product manufacturing, distribution, and sale. His media and entertainment work involves substantial work in licensing IP assets of various types, including managing name, image and likeness deals and the formation of new companies and joint ventures to commercialize new product offerings. For technology-driven companies, he is particularly focused on the development, protection and leveraging of various solutions and their related IP rights, whether they are driven by new technologies (e.g., AI or LLMs) or are more traditional approaches. Many of the technology deals involve the development and commercialization of software, whether as bespoke solutions or standardized products—delivered via the cloud or made available locally. Such deals regularly include the use, protection and monetization of data as well. In many of these transactions, Jim works closely with Venable’s deep bench of IP and regulatory attorneys to cover all aspects of such transactions and his clients’ larger business.
bottom of page